Skip to main content

Athyrium Injects $35mn Into Agendia

Healthcare investor Athyrium Capital has invested $35mn into Agendia, precision oncology firm. The capital will accelerate commercial expansion in the U.S. and international markets, including increasing adoption of Agendia's recently-launched next-generation sequencing-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit. Jeff Ferrell, Partner at Athyrium Capital Management, commented: "We believe the value of Agendia's versatile genomic technologies in delivering precision medicine for patients is clear. Backed by world-class clinical data, recommended by experts internationally and meeting a significant medical need, their tests enable a more effective use of finite healthcare budgets and resources. We are pleased to partner with Agendia and to have the...